Phenoteq

Diagnosis, monitoring and treatment are plagued by inaccuracy. This must change. We use machine learning models that handle billions of variables to outperform current standards of care. Almost 50% of men will have a form of prostate cancer by the time they are 75. Low accuracy in predicting progression means thousands of men undergo life altering surgeries when they don’t need to. Our ML powered targeted assays will save lives and money by being accurate and cheap to deploy. We’re backed by a top team of advisors with decades of experience in the treatment of prostate cancer. HENRY FARMERY Henry wrote his PhD in computational biology and prostate cancer and submitted without corrections at the University of Cambridge. Subsequently, he was the second technical hire at a YC funded genomics company where he led the technical development of their first product. ANGELO CARDOSO Angelo has a MSc in AI (top 1%) and PhD in deep learning from the University of Lisbon. He optimised portfolios as a Quant and after his post-doc led DS/ML teams at ASOS and Vodafone, deploying business impactful projects and presenting them at top academic venues. He has authored 12 publications.